Emcure Pharmaceuticals IPO subscription starts on Wednesday, July 3 and ends on Friday, July 5, 2024. The IPO is a book-built issue of Rs. 1,952.03 crores. The issue is combination of fresh issue of 0.79 crore shares, aggregating to Rs. 800 crores and an offer for sale of up to 1.14 crore shares, aggregating to Rs. 1,152.03 crores. The issue shall be listed on both NSE and BSE with tempting date fixed as Wednesday, July 10, 2024.
Emcure Pharmaceuticals IPO price band fixed at Rs. 960 to Rs. 1008 per equity share with face value of Rs.10 each. The minimum order quantity of the issue is 14 equity shares and in multiples thereof. The minimum amount of investment required for Retail is Rs. 14112. The minimum bid size for sNII is 15 lots (210 shares), amounting to Rs. 211,680. The company has reserved 50% shares of the issue for QIB’s, 15% for NII(HNI)’s and 35% for Retail. The company has given a discount of Rs. 90 to the employees in the issue.
ReadmoreRecord Decline in the share of India’s Imported Coal in Last Decade
Axis Capital Limited, Kotak Mahindra Capital Company Limited, Jefferies India Private Limited and J. P. Morgan India Private Limited are the book-running lead managers. Axis Bank Limited and HDFC Bank Limited are the sponsor bank of the issue. Link Intime India Private Limited is registrar of the IPO.
Financials
| Particulars | 31 Mar2024 | 31 Mar 2023 | 31 Mar 2022 |
| Revenue | 6715.24 | 6031.71 | 5918.86 |
| Profit | 527.57 | 561.84 | 702.56 |
| PAT Margin | 7.86% | 9.31% | 11.87% |
| Cash Flow from Operating activities | 1097.24 | 746.85 | 768.20 |
| Borrowings | 2091.94 | 2202.42 | 2102.19 |
Risk Factors
- The company is dependent on third parties for the distribution and marketing of it’s products.
- The company have experienced negative cash and cash equivalents in the past and may continue to do so in the future.
- Profit and Profit Margins are declining from previous years.
Objects of the Issue
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by our company;
- General Corporate Purposes.
About Emcure Pharmaceuticals Limited
Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and global marketing a broad range of 350+ pharmaceutical products. EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb’24 data. The company has more than 11000+ employees.
One thought on “Emcure Pharmaceuticals IPO subscription on July 3, price sets at Rs.960 to Rs.1008 per share”